The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial, SAKK 19/05.
F. Zappa
Consultant or Advisory Role - Roche
C. Droege
No relevant relationships to disclose
D. C. Betticher
Consultant or Advisory Role - Roche
R. von Moos
Consultant or Advisory Role - Amgen; Novartis; Roche
Honoraria - Amgen; Roche
M. H. Brutsche
Honoraria - Roche
F. Baty
No relevant relationships to disclose
L. Bubendorf
Consultant or Advisory Role - Roche
Honoraria - Roche
A. Ochsenbein
No relevant relationships to disclose
E. Oppliger Leibundgut
No relevant relationships to disclose
O. Gautschi
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
P. Froesch
No relevant relationships to disclose
R. A. Stahel
Consultant or Advisory Role - Roche
Honoraria - Roche
D. Rauch
No relevant relationships to disclose
P. Schmid
No relevant relationships to disclose
M. Mayer
No relevant relationships to disclose
S. Crowe
No relevant relationships to disclose
P. Brauchli
No relevant relationships to disclose
K. Ribi
No relevant relationships to disclose
M. Pless
Consultant or Advisory Role - Roche